Comparative Pharmacology
Head-to-head clinical analysis: HYPAQUE M 90 versus IOPAMIDOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYPAQUE M 90 versus IOPAMIDOL.
HYPAQUE-M,90% vs IOPAMIDOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ionic, high-osmolality iodinated contrast agent that absorbs X-rays, enhancing radiographic contrast by attenuating X-rays in tissues where it distributes.
Iopamidol is a nonionic, water-soluble radiographic contrast agent that attenuates X-rays by increasing the density of vascular structures and organs, thereby enhancing contrast in imaging studies. It does not have a pharmacological mechanism of action but exerts its effect via physical radiopacity.
Intra-arterial or intravenous injection: 30-60 mL of 90% solution, administered as a bolus or infusion over 1-2 minutes; repeat dosing not recommended.
Intravenous or intra-arterial administration; dose varies by procedure (e.g., cerebral angiography: 5-10 mL; coronary arteriography: 3-10 mL per injection; CT: 50-150 mL; adults: up to 200 mL total).
None Documented
None Documented
Terminal half-life: 1-2 hours (normal renal function); prolonged in renal impairment
2 hours; prolonged in renal impairment (up to 30 hours in anuria)
Renal: >95% unchanged; biliary/fecal: <5%
Renal: >90% unchanged; biliary/fecal: <2%
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent